Prazosin for the management of behavioural and psychological symptoms of dementia
Prazosin, a centrally acting α1 adrenoceptor antagonist, has been included in two published algorithms amongst the list of medications that may be used in the management of behavioural and psychological symptoms of dementia (BPSD). However, a review of PubMed, Ovid and Cochrane Collaboration found t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2022-07-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/prazosin-for-the-management-of-behavioural-and-psychological-symptoms-of-dementia |
| _version_ | 1828803187112411136 |
|---|---|
| author | Rajesh R Tampi Deena J Tampi Syeda Arshiya Farheen Mahwish Adnan Dhweeja Dasarathy |
| author_facet | Rajesh R Tampi Deena J Tampi Syeda Arshiya Farheen Mahwish Adnan Dhweeja Dasarathy |
| author_sort | Rajesh R Tampi |
| collection | DOAJ |
| description | Prazosin, a centrally acting α1 adrenoceptor antagonist, has been included in two published algorithms amongst the list of medications that may be used in the management of behavioural and psychological symptoms of dementia (BPSD). However, a review of PubMed, Ovid and Cochrane Collaboration found that there was only one small published randomized controlled trial (RCT) that evaluated the use of prazosin amongst individuals with BPSD. Evidence from this good quality RCT indicates that prazosin appears to benefit individuals with agitation and aggression amongst individuals with BPSD and this medication is well tolerated. When compared to other treatments for BPSD, including atypical antipsychotics, antidepressants, acetylcholinesterase inhibitors, memantine, repetitive transcranial magnetic stimulation and electroconvulsive therapy, where there are multiple studies for each of these treatment modalities, the data for the use of prazosin for BPSD are limited to just one good quality RCT. Given the limitations in available data, the routine use of prazosin for the treatment of BPSD cannot be recommended at this time. However, prazosin may be used for the management of agitation and aggression amongst individuals with dementia when other medication classes, like acetylcholinesterase inhibitors, memantine, antidepressants and/or atypical antipsychotics, have been ineffective or not tolerated. |
| first_indexed | 2024-12-12T07:18:52Z |
| format | Article |
| id | doaj.art-c748bc090c6f436489529d85b78dccf8 |
| institution | Directory Open Access Journal |
| issn | 1740-4398 |
| language | English |
| last_indexed | 2024-12-12T07:18:52Z |
| publishDate | 2022-07-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-c748bc090c6f436489529d85b78dccf82022-12-22T00:33:26ZengBioExcel Publishing LtdDrugs in Context1740-43982022-07-01111910.7573/dic.2022-3-3Prazosin for the management of behavioural and psychological symptoms of dementiaRajesh R TampiDeena J TampiSyeda Arshiya FarheenMahwish AdnanDhweeja DasarathyPrazosin, a centrally acting α1 adrenoceptor antagonist, has been included in two published algorithms amongst the list of medications that may be used in the management of behavioural and psychological symptoms of dementia (BPSD). However, a review of PubMed, Ovid and Cochrane Collaboration found that there was only one small published randomized controlled trial (RCT) that evaluated the use of prazosin amongst individuals with BPSD. Evidence from this good quality RCT indicates that prazosin appears to benefit individuals with agitation and aggression amongst individuals with BPSD and this medication is well tolerated. When compared to other treatments for BPSD, including atypical antipsychotics, antidepressants, acetylcholinesterase inhibitors, memantine, repetitive transcranial magnetic stimulation and electroconvulsive therapy, where there are multiple studies for each of these treatment modalities, the data for the use of prazosin for BPSD are limited to just one good quality RCT. Given the limitations in available data, the routine use of prazosin for the treatment of BPSD cannot be recommended at this time. However, prazosin may be used for the management of agitation and aggression amongst individuals with dementia when other medication classes, like acetylcholinesterase inhibitors, memantine, antidepressants and/or atypical antipsychotics, have been ineffective or not tolerated.https://www.drugsincontext.com/prazosin-for-the-management-of-behavioural-and-psychological-symptoms-of-dementiaaggressionagitationbehavioural and psychological symptoms of dementiaprazosinrandomized controlled trial |
| spellingShingle | Rajesh R Tampi Deena J Tampi Syeda Arshiya Farheen Mahwish Adnan Dhweeja Dasarathy Prazosin for the management of behavioural and psychological symptoms of dementia Drugs in Context aggression agitation behavioural and psychological symptoms of dementia prazosin randomized controlled trial |
| title | Prazosin for the management of behavioural and psychological symptoms of dementia |
| title_full | Prazosin for the management of behavioural and psychological symptoms of dementia |
| title_fullStr | Prazosin for the management of behavioural and psychological symptoms of dementia |
| title_full_unstemmed | Prazosin for the management of behavioural and psychological symptoms of dementia |
| title_short | Prazosin for the management of behavioural and psychological symptoms of dementia |
| title_sort | prazosin for the management of behavioural and psychological symptoms of dementia |
| topic | aggression agitation behavioural and psychological symptoms of dementia prazosin randomized controlled trial |
| url | https://www.drugsincontext.com/prazosin-for-the-management-of-behavioural-and-psychological-symptoms-of-dementia |
| work_keys_str_mv | AT rajeshrtampi prazosinforthemanagementofbehaviouralandpsychologicalsymptomsofdementia AT deenajtampi prazosinforthemanagementofbehaviouralandpsychologicalsymptomsofdementia AT syedaarshiyafarheen prazosinforthemanagementofbehaviouralandpsychologicalsymptomsofdementia AT mahwishadnan prazosinforthemanagementofbehaviouralandpsychologicalsymptomsofdementia AT dhweejadasarathy prazosinforthemanagementofbehaviouralandpsychologicalsymptomsofdementia |